Abstract:Background/Aims: Treatment options for metastatic castrate-resistant prostate cancer (mCRPC) are limited and typically centered on paclitaxel-based chemotherapy. In this study, we aimed to evaluate whether miR-34a attenuates chemoresistance to paclitaxel by regulating target genes associated with drug resistance. Methods: We used data from The Cancer Genome Atlas to compare miR-34a expression levels in prostate cancer (PC) tissues with normal prostate tissues. The effects of miR-34a inhibition and overexpression on PC proliferation were evaluated in vitro via Cell Counting Kit-8 (CCK-8) proliferation, colony formation, apoptosis, and cell-cycle assays. A luciferase reporter assay was employed to identify the interactions between miR-34a and specific target genes. To determine the effects of up-regulation of miR-34a on tumor growth and chemo-resistance in vivo, we injected PC cells overexpressing miR-34a into nude mice subcutaneously and evaluated the rate of tumor growth during paclitaxel treatment. We examined changes in the expression levels of miR-34a target genes JAG1 and Notch1 and their downstream genes via miR-34a transfection by quantitative reverse transcription PCR (qRT-PCR) and western blot assay. Results: miR-34a served as an independent predictor of reduced patient survival. MiR-34a was down-regulated in PC-3PR cells compared with PC-3 cells. The CCK-8 assay showed that miR-34a overexpression resulted in increased sensitivity to paclitaxel while miR-34a down-regulation resulted in chemoresistance to paclitaxel in vitro. A study of gain and loss in a series of functional assays revealed that PC cells expressing miR-34a were chemosensitive. Furthermore, the overexpression of miR-34a increased the sensitivity of PC-3PR cells to chemotherapy in vivo. The luciferase reporter assay confirmed that JAG1 and Notch1 were directly targeted by miR-34a. Interestingly, western blot analysis and qRT-PCR confirmed that miR-34a inhibited the Notch1 signaling pathway. We found that miR-34a increased the chemosensitivity of PC-3PR cells by directly repressing the TCF1/ LEF1 axis. Conclusion: Our results showed that miR-34a is involved in the development of chemosensitivity to paclitaxel. By regulating the JAG1/Notch1 axis, miR-34a or its target genes JAG1 or Notch1 might serve as potential predictive biomarkers of response to paclitaxel-based chemotherapy and/or therapeutic targets that will help to overcome chemoresistance at the mCRPC stage.

Microrna-323 Upregulation Promotes Prostate Cancer Growth and Docetaxel Resistance by Repressing P73

Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells

MiR-138–5p Inhibits Prostate Cancer Cell Proliferation and Chemoresistance by Targeting APOBEC3B

MicroRNA-107 Inhibits Proliferation of Prostate Cancer Cells by Targeting Cyclin E1.

MicroRNA‑328 directly targets p21‑activated protein kinase 6 inhibiting prostate cancer proliferation and enhancing docetaxel sensitivity.

MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells Via Direct Suppression of JAG1/Notch1 Axis

Microrna-372 Suppresses Migration and Invasion by Targeting P65 in Human Prostate Cancer Cells

Mir-1231 is Downregulated in Prostate Cancer with Prognostic and Functional Implications

MicroRNA-195 Regulates Docetaxel Resistance by Targeting Clusterin in Prostate Cancer

Mir-137-3p Modulates the Progression of Prostate Cancer by Regulating the JNK3/EZH2 Axis.

MiR-203 over-expression promotes prostate cancer cell apoptosis and reduces ADM resistance

455-3p is markedly downregulated in prostate cancer cell lines and clinical tumor specimens. Gain-of-function and loss-of- function studies showed that miR-455-3p promotes prostate cancer cell growth both in vitro and in vivo. Bioinformatics analysis and Luciferase reporter assays demonstrated that

Micro-ribonucleic Acid 29b Inhibits Cell Proliferation and Invasion and Enhances Cell Apoptosis and Chemotherapy Effects of Cisplatin Via Targeting of DNMT3b and AKT3 in Prostate Cancer

MicroRNA-30e Inhibits Adhesion, Migration, Invasion and Cell Cycle Progression of Prostate Cancer Cells Via Inhibition of the Activation of the MAPK Signaling Pathway by Downregulating CHRM3

MiR-573 Inhibits Prostate Cancer Metastasis by Regulating Epithelial-Mesenchymal Transition.

MicroRNA-103 suppresses tumor cell proliferation by targeting PDCD10 in prostate cancer.

Silencing of LINC01963 enhances the chemosensitivity of prostate cancer cells to docetaxel by targeting the miR-216b-5p/TrkB axis

Use of Mir-145 and Testicular Nuclear Receptor 4 Inhibition to Reduce Chemoresistance to Docetaxel in Prostate Cancer

miR-31-5p Regulates 14-3-3 ɛ to Inhibit Prostate Cancer 22RV1 Cell Survival and Proliferation via PI3K/AKT/Bcl-2 Signaling Pathway.

Downregulation of Microrna-429 Inhibits Cell Proliferation by Targeting P27kip1 in Human Prostate Cancer Cells.

MicroRNA-302a Suppresses Tumor Cell Proliferation by Inhibiting AKT in Prostate Cancer.